{"DataElement":{"publicId":"4379856","version":"1","preferredName":"Person Prior Therapy Adverse Event Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded yes/no/not applicable response related to whether a person has fully recovered from adverse events as a result of prior agent administration.","longName":"PRTX_AE_CTE_COD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3304301","version":"1","preferredName":"Person Prior Therapy Adverse Event Clinical Trial Eligibility Criteria","preferredDefinition":"Person; a human being._An indicator that a person has been previously treated for the same condition or with the same therapy._Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used._Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"2236731v1.0:3304299v1.0","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"2236731","version":"1","preferredName":"Person","preferredDefinition":"A human being.","longName":"C25190","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Person","conceptCode":"C25190","definition":"A human being.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FC6DF7-66EB-4CAB-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-20","endDate":null,"createdBy":"UMLLOADER_MAGE","dateCreated":"2005-06-20","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3304299","version":"1","preferredName":"Prior Therapy Adverse Event Clinical Trial Eligibility Criteria","preferredDefinition":"An indicator that a person has been previously treated for the same condition or with the same therapy.:Any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, syndrome, or disease, temporally associated with the use of a medical product or procedure, regardless of whether or not it is considered related to the product or procedure (attribution of unrelated, unlikely, possible, probable, or definite). The concept refers to events that could be medical product related, dose related, route related, patient related, caused by an interaction with another therapy or procedure, or caused by opioid initiation or dose escalation. The term also is referred to as an adverse experience. The old term Side Effect is retired and should not be used.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C16124:C41331:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prior Therapy","conceptCode":"C16124","definition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Adverse Event","conceptCode":"C41331","definition":"Any unfavorable or unintended disease, sign, or symptom (including an abnormal laboratory finding) that is temporally associated with the use of a medical treatment or procedure, and that may or may not be considered related to the medical treatment or procedure. Such events can be related to the intervention, dose, route of administration, patient, or caused by an interaction with another drug(s) or procedure(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1CD145F-AD41-78D1-E040-BB89AD436191","latestVersionIndicator":"Yes","beginDate":"2011-11-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-15","modifiedBy":"ONEDATA","dateModified":"2011-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1CD145F-AD52-78D1-E040-BB89AD436191","latestVersionIndicator":"Yes","beginDate":"2011-11-15","endDate":null,"createdBy":"REBOYJ","dateCreated":"2011-11-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876424","version":"1","longName":"Prior Treatments","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"PRTX_AE_CTE_COD_IND","type":"USED_BY","context":"Theradex"},{"name":"TEST","type":"USED_BY","context":"TEST"}],"ReferenceDocuments":[{"name":"Has patient failed to recover","type":"Preferred Question Text","description":"Has patient failed to recover from adverse events due to agents administered more than 4 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Has patient failed to recover to baseline or CTCAE less than or equal to grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant AEs defined as lab elevation with no associated symptoms or  sequelae?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to agents administered?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to agents administered more than 3 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"Has patient failed to recover (less than or equal to grade 1) from adverse events due to agents administered (except for alopecia)?","url":null,"context":"Theradex"},{"name":"Theradex - 5","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events (to grade less than or equal to in severity) due to agents administered more than 4 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Has patient failed to recover from acute adverse events to grade less than 2 or baseline due to agents administered, with exception of alopecia, unless approved by the Protocol Chair?","url":null,"context":"TEST"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Has patient failed to recover from clinically significant adverse events due to prior agents administered to less than or equal to grade 1 or baseline with the exception of alopecia and peripheral neurophathy, unless approved by Protocol Chair?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"Has patient failed to recover (less than or equal to grade 1 or baseline) from adverse events due to agents administered more than 4 weeks earlier (except for alopecia)?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Has patient failed to recover to CTCAE grade 2 or less from serious (CTCAE grade 3 or more) adverse events from the previously received agents?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events (except alopecia) due to agents administered more than 4 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than CTCAE Grade 1 or baseline, with the exception of alopecia)?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to agents administered more than 2 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"Has patient failed to recover from serious adverse events due to agents administered more than 4 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior administered agents as noted above?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Has patient failed to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1)?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1, except alopecia, peripheral sensory neuropathy, and stable endocrine insufficiencies such as thyroid and adrenal insufficiency)?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"Has patient failed to recover from toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1), except alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Has patient failed to recover to less than grade 1 from adverse events due to agents administered more than 3 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Has patient failed to recover to eligibility levels from prior toxicity?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Has patient failed to recover to less than or equal to grade 1 from adverse events due to agents administered more than 3 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events (other than alopecia) due to agents administered more than 3 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., has residual toxicities greater than Grade 1)?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Has patient failed to recover from serious (CTCAE grade 3 or more)  adverse events to grade 2 or less from prior therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1, except for alopecia, neuropathy, lymphocytopenia and other non-clinically significant adverse events)?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events (except alopecia) due to agents administered more than 2 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1), with the exception of patients with less than or equal to grade 2 neuropathy or less than or equal to grade 2 alopecia who may qualify for the study?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Has patient failed to recover to grade 1 or less (except alopecia) from adverse events due to agents administered more than 4 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Has patient failed to recover from clinically significant adverse events (other than alopecia) due to prior anti-cancer therapy?","url":null,"context":"Theradex"},{"name":"Theradex -  33","type":"Alternate Question Text","description":"Has patient failed to recover to grade less than or equal to 1 from adverse events (other than alopecia) due to agents administered more than 3 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Has patient failed to recover to grade less than or equal to 1 adverse events (other than alopecia) due to agents administered more than 3 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy to grade 1 or baseline?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., has residual toxicities greater than Grade 1), except for Grade 2 anorexia, alopecia, neuropathy, and fatigue, for which resolution is not required?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Has patient failed to recover from toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, grade 0 or 1, or to levels dictated in the eligibility criteria with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Has patient failed to recover from serious (CTCAE grade 3 or higher) adverse events to grade 1 or less from prior therapies?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1 except peripheral neuropathy)?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier (i.e., has residual toxicities greater than Grade 1)?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Has patient failed to recover to baseline or CTCAE less than or equal to Grade 1 from adverse events due to all prior anti-cancer therapies except alopecia, oxaliplatin-related neuropathy, and other non-clinically significant adverse events?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Has patient failed to recover from all non-hematologic adverse events of prior chemotherapy, surgery, or radiotherapy, except alopecia, to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade less than or equal to 2 prior to starting therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1, except alopecia) that was administered more than four weeks prior to starting study therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Has patient failed to recover adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia, or peripheral neuropathy (up to Grade 2 is permitted)?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Has patient failed to recover (resolved or stabilized) from adverse events due to agents administered more than 4 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to previously administered agents?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Has patient failed to recover from major side effects, or open biopsy within 7 days before start of study treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Did patient receive prior therapy with a checkpoint inhibitor and was taken off drug for serious adverse events?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., has residual toxicities greater than Grade 1), except for grade 2 peripheral sensory neuropathy?","url":null,"context":"Theradex"},{"name":"Theradex - 51","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy except hair loss and peripheral neuropathy (i.e., have residual toxicities greater than Grade 1)?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Has patient failed to recover to less than or equal to grade 1 from persistent toxicities caused by previous anticancer therapy,  excluding alopecia, or should be stable chronic grade 2 toxicities that do not overlap with presumed toxicities of olaparib and/or AZD6738?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Has patient failed to recover from greater than or equal to  grade 2 adverse events due to prior anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria?","url":null,"context":"Theradex"},{"name":"Theradex - 52","type":"Alternate Question Text","description":"Have adverse events (excluding alopecia) due to agents administered more than 4 weeks earlier recovered to less than Grade 1?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1), except alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1, except for alopecia or neuropathy)?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., has residual toxicities greater than Grade 1 per CTCAE v.5)?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Has patient not recovered from adverse events due to prior anti-cancer therapy (i.e. have residual toxicities greater than grade 1) with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1, except for alopecia and neuropathy less than or equal to grade 2)?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy   (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Has patient not recovered to grade 1 or better from adverse events due to prior anti-cancer therapy (not including Cycle 1 of EPOCH, CHOP, or CHOPE if received off protocol) within 14 days prior to enrollment, with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Has patient failed to recover from AEs due to prior anti-cancer therapy (i.e., have not returned to baseline or have residual toxicities greater than grade 1) with the exception of less than or equal to grade 2 neuropathy and alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Have all non-hematological adverse events of any prior chemotherapy, surgery, or radiotherapy, except alopecia, resolved to NCI-CTCAE Grade less than or equal to 2 prior to starting therapy?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Has patient failed to recover from greater than or equal to grade 2 adverse events due to prior anti-cancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than grade 1) with the exceptions of alopecia and endocrinopathies from prior immunotherapy-based treatments that are well controlled with hormone replacement?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior mFOLFOX6 chemotherapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Has patient failed to recover to eligibility levels from prior toxicity or adverse events?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia, thyroid dysfunction or neuropathy?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events (except alopecia or neuropathy) due to agents administered more than 4 weeks earlier?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"Has patient failed to recover from clinically significant adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of neuropathy, which should resolve to grade 2, or alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Has patient failed to recover from acute clinically significant adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"Has patient failed to recover from clinically significant adverse events of their most recent therapy/intervention prior to enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"Has patient failed to recover from clinically-significant adverse events of their most recent cancer immunotherapy to grade 1 or less, (with the exception of alopecia and lymphopenia)?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Has patient failed to recover from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities greater than Grade 1) with the exception of alopecia?","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3AFC98-6CF0-D1F7-E040-BB89AD432DC8","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-07-02","modifiedBy":"SOKKERL","dateModified":"2023-12-28","changeDescription":"Theradex_ghd_07-02-14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}